Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Metastasis-associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer.

Du B, Yang ZY, Zhong XY, Fang M, Yan YR, Qi GL, Pan YL, Zhou XL.

World J Gastroenterol. 2011 Mar 7;17(9):1219-26. doi: 10.3748/wjg.v17.i9.1219.

2.

Prognostic impact of CD168 expression in gastric cancer.

Ishigami S, Ueno S, Nishizono Y, Matsumoto M, Kurahara H, Arigami T, Uchikado Y, Setoyama T, Arima H, Yoshiaki K, Kijima Y, Kitazono M, Natsugoe S.

BMC Cancer. 2011 Mar 24;11:106. doi: 10.1186/1471-2407-11-106.

3.

Gene profiling of MTA1 identifies novel gene targets and functions.

Ghanta KS, Li DQ, Eswaran J, Kumar R.

PLoS One. 2011 Feb 25;6(2):e17135. doi: 10.1371/journal.pone.0017135.

4.

TGF-β1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells.

Pakala SB, Singh K, Reddy SD, Ohshiro K, Li DQ, Mishra L, Kumar R.

Oncogene. 2011 May 12;30(19):2230-41. doi: 10.1038/onc.2010.608. Epub 2011 Jan 24.

5.

RHAMM/ERK interaction induces proliferative activities of cementifying fibroma cells through a mechanism based on the CD44-EGFR.

Hatano H, Shigeishi H, Kudo Y, Higashikawa K, Tobiume K, Takata T, Kamata N.

Lab Invest. 2011 Mar;91(3):379-91. doi: 10.1038/labinvest.2010.176. Epub 2010 Oct 18.

6.

Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells.

Kumar R, Balasenthil S, Pakala SB, Rayala SK, Sahin AA, Ohshiro K.

Cancer Res. 2010 Aug 15;70(16):6598-608. doi: 10.1158/0008-5472.CAN-10-0907.

7.

MTA1 coregulator regulates LPS response via MyD88-dependent signaling.

Pakala SB, Reddy SD, Bui-Nguyen TM, Rangparia SS, Bommana A, Kumar R.

J Biol Chem. 2010 Oct 22;285(43):32787-92. doi: 10.1074/jbc.M110.151340. Epub 2010 Aug 11.

8.

RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity.

Tolg C, Hamilton SR, Morningstar L, Zhang J, Zhang S, Esguerra KV, Telmer PG, Luyt LG, Harrison R, McCarthy JB, Turley EA.

J Biol Chem. 2010 Aug 20;285(34):26461-74. doi: 10.1074/jbc.M110.121491. Epub 2010 Jun 17.

9.

Regulated degradation of spindle assembly factors by the anaphase-promoting complex.

Song L, Rape M.

Mol Cell. 2010 May 14;38(3):369-82. doi: 10.1016/j.molcel.2010.02.038.

10.

RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M.

Neoplasia. 2009 Sep;11(9):956-63.

11.

MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions.

Reddy SD, Pakala SB, Ohshiro K, Rayala SK, Kumar R.

Cancer Res. 2009 Jul 15;69(14):5639-42. doi: 10.1158/0008-5472.CAN-09-0898. Epub 2009 Jul 7.

12.

RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53.

Sohr S, Engeland K.

Cell Cycle. 2008 Nov 1;7(21):3448-60. Epub 2008 Nov 17.

PMID:
18971636
13.

Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.

Zlobec I, Terracciano L, Tornillo L, Günthert U, Vuong T, Jass JR, Lugli A.

Gut. 2008 Oct;57(10):1413-9. doi: 10.1136/gut.2007.141192. Epub 2008 Apr 24.

PMID:
18436576
14.

Hyaluronan-mediated motility: a target in oral squamous cell carcinoma.

Yamano Y, Uzawa K, Shinozuka K, Fushimi K, Ishigami T, Nomura H, Ogawara K, Shiiba M, Yokoe H, Tanzawa H.

Int J Oncol. 2008 May;32(5):1001-9.

PMID:
18425326
15.

MTA family of coregulators in nuclear receptor biology and pathology.

Manavathi B, Singh K, Kumar R.

Nucl Recept Signal. 2007 Nov 30;5:e010. doi: 10.1621/nrs.05010. Review.

16.

MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.

Molli PR, Singh RR, Lee SW, Kumar R.

Oncogene. 2008 Mar 27;27(14):1971-80. Epub 2007 Oct 8.

17.

Network modeling links breast cancer susceptibility and centrosome dysfunction.

Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, Assmann V, Elshamy WM, Rual JF, Levine D, Rozek LS, Gelman RS, Gunsalus KC, Greenberg RA, Sobhian B, Bertin N, Venkatesan K, Ayivi-Guedehoussou N, Solé X, Hernández P, Lázaro C, Nathanson KL, Weber BL, Cusick ME, Hill DE, Offit K, Livingston DM, Gruber SB, Parvin JD, Vidal M.

Nat Genet. 2007 Nov;39(11):1338-49. Epub 2007 Oct 7.

PMID:
17922014
18.

Identification of Pax5 as a target of MTA1 in B-cell lymphomas.

Balasenthil S, Gururaj AE, Talukder AH, Bagheri-Yarmand R, Arrington T, Haas BJ, Braisted JC, Kim I, Lee NH, Kumar R.

Cancer Res. 2007 Aug 1;67(15):7132-8. Erratum in: Cancer Res. 2015 Jun 15;75(12):2580-1.

19.

The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.

Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J, Turley EA.

J Biol Chem. 2007 Jun 1;282(22):16667-80. Epub 2007 Mar 28.

20.

Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair.

Tolg C, Hamilton SR, Nakrieko KA, Kooshesh F, Walton P, McCarthy JB, Bissell MJ, Turley EA.

J Cell Biol. 2006 Dec 18;175(6):1017-28. Epub 2006 Dec 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk